[Influence of preventive use of vasopressin tannate on diabetes insipidus and serum sodium at the early postoperation of craniopharyngioma].
To explore the influence of preventive use of vasopressin tannate on diabetes insipidus and serum sodium at the early postoperation of craniopharyngioma.  Methods: The data of 83 patients, who underwent unilateral sub-frontal approach resection of craniopharyngioma between 2010 and 2014 by the same senior neurosurgeon, were retrospectively analyzed. The patients were divided into a vasopressin tannate group (used group) and a control group. The diabetes insipidus and serum sodium changes were compared between the two groups.  Results: Compared with the control group, the incidence of diabetes insipidus decreased at the early postoperation in the vasopressin tannate group (P<0.05). There was high incidence of diabetes insipidus in patients with pituitary stalk excision and tumor close adhesion to the third ventricle floor at the early postoperation (P<0.05). Under such conditions, the incidence of diabetes insipidus in the vasopressin tannate group was decreased compared with the control group (P<0.05). Postoperative hypernatremia occurred in 37 patients (44.6%), and hyponatremia occurred in 60 patients (72.3%), the average time of the occurrence of hpernatremia and hyponatremia was 1.4 and 3.7 days after surgery. Postoperative high serum sodium and low serum sodium appeared alternately in 19 patients (22.9%). There was significant difference in the serum sodium distribution in the first day after surgery in both groups (P<0.05), and the percent of hpernatremia in the vasopressin tannate group was significantly less than that in the control group (P<0.05).  Conclusion: Preventive use of vasopressin tannate can effectively reduce diabetes insipidus and hypernatremia incidence at the early postoperative stage after microsurgery for craniopharyngioma.
Department of Neurosurgery, Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu Zhejiang 322000, China.
Tao
T
Xiong
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Siyi
S
Wanggou
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Xuejun
X
Li
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Qing
Q
Liu
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Xingjun
X
Jiang
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Zefeng
Z
Peng
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Xianrui
X
Yuan
D001127:Arginine Vasopressin / Q000627:therapeutic use*; D003397:Craniopharyngioma / Q000150:complications* / Q000601:surgery; D003919:Diabetes Insipidus / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006955:Hypernatremia / Q000453:epidemiology / Q000517:prevention & control*; D007010:Hyponatremia / Q000453:epidemiology; D015994:Incidence; D008297:Male; D008866:Microsurgery / Q000009:adverse effects*; D010902:Pituitary Gland / Q000601:surgery; D010911:Pituitary Neoplasms; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D012189:Retrospective Studies
C016671:pitressin tannate; D001127:Arginine Vasopressin